Janssen vaccine will not be administered pending the completion of the investigation of thrombosis cases in the USA

Following the recommendation from Johnson&Johnson to the member states of the European Union, the batch of 2,400 Janssen vaccines received on 14 April, in Cyprus, **will not be made available, for the time being,** within the framework of the National Vaccination Plan.

The recommendation by the manufacturing company **was offered as a precaution pending the completion of the investigation on the possibility of thrombosis cases** recorded in the United States being associated with the vaccine. At the same time, the scientific opinion from the European Medicines Agency is expected, to which the data from the USA were conveyed.

More information will be communicated when the assessment is completed by the competent Medicines Agency of the USA and of the European Union.

14.04.2021